Surveillance Intensity Comparison by Risk for T1NX Locally Excised Rectal Adenocarcinoma: a Cost-Effective Analysis.

BACKGROUND: Controversy exists regarding the optimal surveillance strategy following local excision of T1NX rectal adenocarcinoma. This study aims to determine the cost-effectiveness of surveillance strategies for locally excised T1NX rectal adenocarcinoma based on histopathologic and local staging risk factors. METHODS: A Markov model with 10-year follow-up was developed for cost-effectiveness analysis of high-, medium-, and low-intensity surveillance strategies after local excision of T1NX rectal adenocarcinoma. Literature review and expert consensus were utilized to populate state/transition probabilities and rewards. Based on this data, 87% of T1NX patients undergoing local excision were low risk. Healthcare utilization costs were based on Centers for Medicare and Medicaid Services data. The primary outcomes were costs in 2018 US dollars and effectiveness in life-years presented as net monetary benefit and incremental cost-effectiveness ratios. One-way sensitivity and probabilistic sensitivity analyses were performed. RESULTS: Net monetary benefit for low-, medium-, and high-intensity surveillance strategies ($393,117.00, $397,978.80, and $397,290.00) shows medium-intensity surveillance to be optimal. One-way sensitivity analysis shows medium-intensity surveillance to be optimal when the cohort is 73-94% low risk. High-intensity surveillance is preferred when less than 73% of the cohort is low risk. Low-intensity surveillance is preferred when greater than 94% is low risk. Probabilistic sensitivity analysis of the base-case shows medium-intensity surveillance is the optimal strategy for 51.5% of the iterations performed. CONCLUSIONS: Medium-intensity surveillance is the most cost-effective surveillance strategy for locally excised T1NX rectal adenocarcinoma in a clinically representative population model.

Routine bilateral central lymph node clearance for papillary thyroid cancer.

BACKGROUND: Controversy exists regarding the extent of surgical treatment for paratracheal (level VI) lymph nodes in patients with papillary thyroid cancer (PTC). Local recurrence within lymph nodes in the central neck compartment after total thyroidectomy can be difficult to detect and more hazardous to treat surgically. An initial bilateral central lymph node dissection (CLND) can best minimize this risk of local recurrence, if CLND is established as reasonably safe and oncologically justified. METHODS: This study is based on a retrospective review of the institutional tumor registry of all patients treated for PTC between January 2000 and May 2008 at a 636-bed tertiary referral center and university-affiliated hospital. The following data were analyzed: the operative procedures, tumor characteristics (size, lymph node metastasis), injury to the recurrent laryngeal nerve (RLN), tumor recurrence, and need for further operative procedures. RESULTS: Of 310 patients identified as treated surgically for PTC, 281 received total thyroidectomy and 29 received a lesser operation. Bilateral CLND was performed in 169 patients, unilateral CLND in 11, and no CLND in 130. The central lymph nodes were positive in 84 (46.7%) of 180 patients with CLND. Excluding isthmus tumors and those with bilateral same-size PTC, 41 (25.5%) of 161 patients with bilateral CLND had positive contralateral lymph nodes. Of the 603 RLNs at risk, 13 temporary injuries occurred, and 8 (1.3%) permanent injuries resulted. The risk of RLN injury was not greater with bilateral CLND compared to unilateral or no CLND (P = .18), and those patients with bilateral CLND had statistically larger tumors (1.60 cm vs 0.84 cm; P < .0001). Of the 10 documented cancer recurrences requiring reoperation, 4 were in the central neck, and all of these occurred in patients who did not have CLND. CONCLUSION: Lymph node metastases are present in both the ipsilateral and contralateral central lymph node basins in a significant percentage of patients with PTC. Routine bilateral CLND in patients with PTC has the potential to clear metastatic disease without significantly increasing the risk of RLN injury.